File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis

TitleIncidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2007
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
Citation
Clinical Gastroenterology And Hepatology, 2007, v. 5 n. 8, p. 938-945.e4 How to Cite?
AbstractBackground & Aims: Independent predictors of hepatocellular carcinoma in patients with cirrhosis are not well established. Methods: We created a cohort of 2126 patients (41% with hepatitis C virus [HCV] infection) who sought care from all Veterans Affairs health care centers in the northwest United States from 1994 to 2005 and who had a diagnosis of cirrhosis recorded in inpatient or outpatient medical records. Results: During a mean follow-up period of 3.6 years, 100 patients were diagnosed with hepatocellular carcinoma (incidence, 1.3 per 100 patient-years). Important predictors of hepatocellular carcinoma in multivariate models included HCV infection (adjusted hazard ratio [ahr], 3.0; 95% confidence interval [CI], 1.7-5.3); hepatitis B virus (HBV) surface antigen (ahr, 3.3; 95% CI, 1.4-7.7); HBV core antibody (ahr, 1.7; 95% CI, 1.1-2.8); obesity (ahr, 2.5; 95% CI, 1.3-4.9), and overweight (ahr, 2.8; 95% CI, 1.5-5.4) relative to patients with a body mass index of < 25 kg/m2, diabetes (ahr, 1.5; 95% CI, 0.9-2.5), and low platelet count (relative to patients with a platelet count of >266 thousands/μL, the ahr was 2.1 [95% CI, 0.8-5.6] in patients with a platelet count of 180-266 thousands/μL, 3.3 [95% CI, 1.3-8.0] in patients with a platelet count of 111-179 thousands/μL, and the ahr was 4.7 [95% CI, 2.0-11.4] in patients with a platelet count of ≤110 thousands/μL). Conclusions: We identified 6 important predictors of hepatocellular carcinoma in multivariate models (including relatively novel predictors such as increased body mass index, HBV core antibody, and low platelet count), which suggest a means of predicting the risk of hepatocellular carcinoma in patients with cirrhosis and optimizing surveillance strategies. © 2007 AGA Institute.
Persistent Identifierhttp://hdl.handle.net/10722/92471
ISSN
2023 Impact Factor: 11.6
2023 SCImago Journal Rankings: 3.091
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorIoannou, GNen_HK
dc.contributor.authorSplan, MFen_HK
dc.contributor.authorWeiss, NSen_HK
dc.contributor.authorMcDonald, GBen_HK
dc.contributor.authorBeretta, Len_HK
dc.contributor.authorLee, SPen_HK
dc.date.accessioned2010-09-17T10:47:16Z-
dc.date.available2010-09-17T10:47:16Z-
dc.date.issued2007en_HK
dc.identifier.citationClinical Gastroenterology And Hepatology, 2007, v. 5 n. 8, p. 938-945.e4en_HK
dc.identifier.issn1542-3565en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92471-
dc.description.abstractBackground & Aims: Independent predictors of hepatocellular carcinoma in patients with cirrhosis are not well established. Methods: We created a cohort of 2126 patients (41% with hepatitis C virus [HCV] infection) who sought care from all Veterans Affairs health care centers in the northwest United States from 1994 to 2005 and who had a diagnosis of cirrhosis recorded in inpatient or outpatient medical records. Results: During a mean follow-up period of 3.6 years, 100 patients were diagnosed with hepatocellular carcinoma (incidence, 1.3 per 100 patient-years). Important predictors of hepatocellular carcinoma in multivariate models included HCV infection (adjusted hazard ratio [ahr], 3.0; 95% confidence interval [CI], 1.7-5.3); hepatitis B virus (HBV) surface antigen (ahr, 3.3; 95% CI, 1.4-7.7); HBV core antibody (ahr, 1.7; 95% CI, 1.1-2.8); obesity (ahr, 2.5; 95% CI, 1.3-4.9), and overweight (ahr, 2.8; 95% CI, 1.5-5.4) relative to patients with a body mass index of < 25 kg/m2, diabetes (ahr, 1.5; 95% CI, 0.9-2.5), and low platelet count (relative to patients with a platelet count of >266 thousands/μL, the ahr was 2.1 [95% CI, 0.8-5.6] in patients with a platelet count of 180-266 thousands/μL, 3.3 [95% CI, 1.3-8.0] in patients with a platelet count of 111-179 thousands/μL, and the ahr was 4.7 [95% CI, 2.0-11.4] in patients with a platelet count of ≤110 thousands/μL). Conclusions: We identified 6 important predictors of hepatocellular carcinoma in multivariate models (including relatively novel predictors such as increased body mass index, HBV core antibody, and low platelet count), which suggest a means of predicting the risk of hepatocellular carcinoma in patients with cirrhosis and optimizing surveillance strategies. © 2007 AGA Institute.en_HK
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cghen_HK
dc.relation.ispartofClinical Gastroenterology and Hepatologyen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.titleIncidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosisen_HK
dc.typeArticleen_HK
dc.identifier.emailLee, SP: sumlee@hku.hken_HK
dc.identifier.authorityLee, SP=rp01351en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.cgh.2007.02.039en_HK
dc.identifier.pmid17509946-
dc.identifier.scopuseid_2-s2.0-34547143659en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34547143659&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issue8en_HK
dc.identifier.spage938en_HK
dc.identifier.epage945.e4en_HK
dc.identifier.isiWOS:000248714400012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridIoannou, GN=35595023000en_HK
dc.identifier.scopusauthoridSplan, MF=17347170200en_HK
dc.identifier.scopusauthoridWeiss, NS=35406927700en_HK
dc.identifier.scopusauthoridMcDonald, GB=7203029062en_HK
dc.identifier.scopusauthoridBeretta, L=7005190156en_HK
dc.identifier.scopusauthoridLee, SP=7601417497en_HK
dc.identifier.citeulike1453351-
dc.identifier.issnl1542-3565-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats